Sponsored by
GT Medical Technologies announced interim results from its Phase 3 trial investigating the use of GammaTiles in patients with newly diagnosed operable brain metastases. GammaTiles are small, bioabsorbable collagen tiles with embedded radiation seeds that can be placed along the walls of the surgical cavity after tumor removal. They immediately begin delivering a low, targeted dose of radiation to the surrounding tissue.
So far, the trial has shown that GammaTiles reduced the risk of tumor recurrence or death by 50% compared to standard of care (surgery followed by stereotactic radiosurgery [SRS] after recovery). Importantly, the rate of side effects was low and comparable in both groups. The interim results are based on 168 of the 230 patients enrolled in the trial, but we hope to see similar results as complete data from all enrolled participants matures. GammaTile is already FDA cleared for use in newly diagnosed and recurrent malignant brain tumors.